Prima reports response data from Phase IIb of IMP321 in breast cancer

Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD) reported additional data from 15 evaluable patients with hormone receptor-positive metastatic breast cancer in the open-label portion of the European Phase IIb

Read the full 279 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE